Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens.

IF 3.4 2区医学 Q3 IMMUNOLOGY

AIDS Pub Date : 2025-03-15 Epub Date: 2025-02-27 DOI:10.1097/QAD.0000000000004072

Michele Bellomo, Nicola Gianotti, Hamid Hasson, Diana Canetti, Silvia Nozza, Monica Guffanti, Emanuela Messina, Vincenzo Spagnuolo, Riccardo Lolatto, Sara Diotallevi, Antonella Castagna, Laura Galli, Camilla Muccini

引用次数: 0

Abstract

In this observational cohort study, the objective was to compare low-density lipoprotein (LDL) cholesterol dynamics in people with HIV (PWH) who switched to a regimen containing doravirine (DOR), rilpivirine, dolutegravir, or bictegravir and were naïve to the studied drugs. Generalized additive mixed models were used to examine LDL cholesterol dynamics. LDL cholesterol was measured in 2381 PWH: during the first two years, DOR had the greatest lowering effect and showed the most favorable lipid outcome.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS 医学-病毒学

CiteScore

5.90

自引率

5.30%

发文量

478

审稿时长

3 months

期刊介绍： Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.